All Outputs (3)

Improving Shared Decision Making Between Patients and Clinicians: Design and Development of a Virtual Patient Simulation Tool. (2018)
Journal Article
Jacklin, S., Maskrey, N., & Chapman, S. (2018). Improving Shared Decision Making Between Patients and Clinicians: Design and Development of a Virtual Patient Simulation Tool. JMIR Medical Education, e10088 - ?. https://doi.org/10.2196/10088

BACKGROUND: Shared decision making (SDM) involves the formation of a collaborative partnership between the patient and clinician combining both of their expertise in order to benefit decision making. In order for clinicians to be able to carry out th... Read More about Improving Shared Decision Making Between Patients and Clinicians: Design and Development of a Virtual Patient Simulation Tool..

Virtual patient educational programme to teach counselling to clinical pharmacists: development and proof of concept (2018)
Journal Article
Richardson, C. L., Chapman, S., & White, S. (2019). Virtual patient educational programme to teach counselling to clinical pharmacists: development and proof of concept. BMJ Simulation and Technology Enhanced Learning, 5(3), 167-169. https://doi.org/10.1136/bmjstel-2018-000352

Pharmacist–patient counselling can benefit patients and optimise care, but appropriate training is required. A virtual patient (VP) tool to teach pharmacists non-vitamin K oral anticoagulant counselling was developed; the VP may be used for continuin... Read More about Virtual patient educational programme to teach counselling to clinical pharmacists: development and proof of concept.

The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis (2018)
Journal Article
Aladul, M. I., Fitzpatrick, R. W., & Chapman, S. R. (2019). The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Research in Social and Administrative Pharmacy, 15(3), 310-317. https://doi.org/10.1016/j.sapharm.2018.05.009

Background: The approval of new biosimilars of infliximab, etanercept and adalimumab by the European Medicines Agency is expected to produce further cost savings to the healthcare system budget. Objectives: This study aimed to estimate the budg... Read More about The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.